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Abstract
To assess the comparative effectiveness and safety of novel biologic therapies in psoriatic arthritis (PsA) and to establish 
the position of the non-anti-tumor necrosis factor α (TNF-α) biologic drugs in the treatment regimen of the disease. A sys-
tematic review and network meta-analysis (NMA) was conducted according to the preferred reporting items for systematic 
reviews and meta-analyses (PRISMA) requirements. Two investigators identified the studies, abstracted data, and assessed 
the risk of bias independently. The NMA was conducted for efficacy [American College of Rheumatology (ACR) criteria, 
ACR20 and ACR50; psoriasis area and severity index (PASI), PASI75] and safety outcomes [any adverse events (AEs) and 
serious adverse events (SAEs)]; treatments were ranked using the P score for each outcome. The PROSPERO registration 
number was 42017072200. MEDLINE/PubMed, Embase, Cochrane Library, and ClinicalTrials.gov were searched from the 
inception of each database to July 10, 2017. Randomized controlled trials (RCTs) for abatacept, apremilast, secukinumab 
or ustekinumab in adults with moderate and severe PsA were included. The overall PsA population and anti-TNF-α-naive, 
anti-TNF-α-failure, or anti-TNF-α-experienced subpopulations were considered. We identified eight eligible RCTs and 
included them in the systematic review and NMA. Significant differences in ACR20 response rate were revealed between 
secukinumab 150 mg and apremilast 20 mg [relative risk; RR = 2.55 (CI—confidence interval; 1.24, 5.23)] and between 
secukinumab 300 mg and apremilast 20 or 30 mg [RR = 3.57 CI (1.48, 8.64) and RR = 2.84 CI (1.18, 6.86), respectively]. 
Any AEs occurred more often in apremilast 20 and 30 mg compared with placebo [RR = 0.58 CI (0.45, 0.74) and RR = 0.58 
CI (0.45, 0.75), respectively] but also compared with secukinumab 150 mg [RR = 0.54 CI (0.35, 0.81) and RR = 0.45 CI 
(0.35, 0.82), respectively]. No significant differences were revealed for SAEs among biologics and between biologics and 
placebo. In the overall population, as well as in the anti-TNF-α-naive subpopulation, secukinumab at a dose of 300 and 
150 mg was ranked the highest for the ACR20 endpoint, while in the anti-TNF-α-experienced subpopulation, secukinumab 
300 mg and apremilast 30 mg revealed the highest rank. Secukinumab 75 mg was the safest drug in terms of any AEs, but 
for SEAs the safest was ustekinumab 90 mg. Our study revealed no significant differences among non-anti-TNF-α biologics 
in the treatment of PsA in the comparisons performed with regards to the highest efficacy and safety. Both in the overall 
population and in the analyzed subpopulations, secukinumab 300 mg was ranked the highest for the ACR20 response rate. 
Secukinumab 300 mg was the safest drug in terms of any AEs, and ustekinumab 90 mg presented the lowest overall risk of 
SAEs. Head-to-head trials and evaluation of comparative efficacy and safety between non-TNF-α biologics are warranted to 
inform clinical decision making with a relevant treatment paradigm.
Keywords Biologics · Biologic drugs · Pharmacotherapy · Network meta-analysis · Systematic review
Introduction
Psoriatic arthritis (PsA) is a chronic autoimmune disease 
classified as a seronegative spondyloarthropathy; inflam-
matory process of the vertebral column, joints, fingers, and 
toes, as well as other arthropathies are the main symptoms 
of this condition. The disease has a significant impact on 
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patients’ functioning and quality of life [1, 2]. PsA is asso-
ciated with an increased morbidity and mortality, result-
ing in a reduced quality of life and productivity [3]. The 
prevalence of PsA is higher among patients with psoriasis, 
with skin lesions typically preceding joint inflammation 
by several years and a prevalence rate ranging from 7 to 
26% [4, 5].
Conventional treatment for PsA usually begins from dis-
ease-modifying antirheumatic drugs (DMARDs) and non-
steroidal anti-inflammatory drugs (NSAIDs). If this treat-
ment is not effective or patients are intolerant, other biologic 
therapies should be used. In the European Union, there are 
registered biologic drugs designed to block the activity of 
an inflammation cytokine, called tumor necrosis factor (anti-
TNF)-α inhibitors (such as infliximab, adalimumab, goli-
mumab, etanercept) [6]. Appropriate treatment is aimed at 
slowing down the disease progression and/or relieving the 
symptoms and achieving clinical remission [7]. In patients 
with intolerance or primary or secondary nonresponsive-
ness to anti-TNF-α, another class of biologic drugs should 
be administered. Several new biologic agents have emerged 
in recent years along with improvements in the understand-
ing of the pathogenesis of PsA and have been claimed to be 
effective in randomized controlled trials (RCTs): abatacept, 
apremilast, secukinumab and ustekinumab [6].
Abatacept is a soluble, fully human fusion protein con-
sisting of the extracellular domain of cytotoxic T-lympho-
cyte antigen 4 (CTLA-4) linked to a modified Fc portion 
of human IgG1. It selectively inhibits T-cell activation via 
competitive binding to CD80 or CD86 and decreases the 
serum levels of cytokines and inflammatory proteins impli-
cated in the pathogenesis of PsA [8]. Apremilast is an oral 
phosphodiesterase-4 inhibitor that has been shown to regu-
late inflammatory mediator inhibiting the expression of 
inflammatory cytokines and increasing the expression of 
anti-inflammatory mediators such as interleukin (IL) 10 [9, 
10]. Secukinumab is a human immunoglobulin-G1 mono-
clonal antibody that selectively binds to and neutralizes 
IL-17A. Increased levels of cells that produce IL-17A have 
been observed in the circulation, joints, and skin plaques 
of patients with PsA, and these levels have been shown to 
correlate with measures of disease activity [11–13]. Usteki-
numab is a human immunoglobulin G1 that binds to the 
common p40 subunit shared by IL-12 and IL-23 involved 
in the pathogenesis of PsA [14].
The drugs were registered for therapy of PsA by the 
US Federal Drug and Food Administration (FDA) and the 
European Medicines Agency (EMA) [6]; ustekinumab was 
registered in 2013 by the FDA and in 2009 by the EMA, 
apremilast in 2014 by the FDA and in 2015 by the EMA, 
secukinumab in 2016 by the FDA and in 2015 by the EMA, 
and abatacept was authorized for the condition in July 2017 
in the USA and in August 2017 by the EMA [6, 15, 16].
According to the summary of product characteristics, 
ustekinumab should be used for a period of 28  weeks; 
therefore, the revealed data for 24 weeks of follow-up were 
considered appropriate for the assessment of this drug [14]. 
Apremilast should be administered for a period of 24 weeks, 
thus the reference studies which provided results for this 
follow-up period were deemed adequate for evaluation [10]. 
According to the marketing authorization, secukinumab 
should be administered for 16 weeks; however, in some 
patients, it could be administered for a longer period. There-
fore, the inclusion of data for 16–24 weeks was also consid-
ered adequate [13]. For abatacept, a period of up to 6 months 
(24–26 weeks) is required, thus the reference clinical trials 
proved relevant for a credible efficacy assessment [16].
Activity of the disease is usually presented with a number 
of parameters included in the American College of Rheu-
matology 20% improvement criteria (ACR20). ACR20 
is defined by the following three conditions: at least 20% 
improvement in the number of tender joints (based on 68 
joints), at least 20% improvement in the number of swollen 
joints (based on 66 joints), and at least 20% improvement in 
three of five additional domains (patient’s global assessment, 
physician’s global assessment, pain, disability measured by 
the health assessment questionnaire, and acute-phase reac-
tant measured by C-reactive protein levels) [17].
Skin involvement was assessed using the psoriasis area 
and severity index (PASI). The PASI was used to assess the 
response of psoriasis, rated as 50% improvement (PASI50), 
75% improvement (PASI75), and 95% improvement 
(PASI90). The PASI is defined as the degree of erythema, 
induration, and desquamation of skin lesions and the area 
affected with psoriasis [17].
A group of patients with PsA do not tolerate or do not 
have a satisfactory response to either NSAIDs, nor non-
biologic DMARDs; about 25–50% of patients are non-
responsive to anti-TNF-α drugs [18, 19]. Therefore, non-
anti-TNF-α biologic agents have emerged as second-line 
therapy in such situations. However, the comparative effi-
cacy of these agents remains unknown as head-to-head RCTs 
are not available.
No direct studies on relative effectiveness of any drugs in 
the therapy of patients with PsA have been published so far, 
so data on the relative efficacy of the novel agents (abata-
cept, apremilast, secukinumab, or ustekinumab) are still una-
vailable. Conventional meta-analysis is unable to resolve this 
issue owing to its incapability of comparing three or more 
treatments; therefore, it is difficult to integrate information 
on the relative efficacy of all tested regimens. On the other 
hand, a network meta-analysis (NMA) can provide a com-
prehensive and coherent set of comparisons based on avail-
able evidence.
In a recent NMA, Song and Lee [18] compared apre-
milast, secukinumab, and ustekinumab for induction of 
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ACR20 response and safety profile (severe adverse events 
or SAEs rate) in the overall population included in clinical 
trials. They found no significant differences between treat-
ments; however, the studies included were heterogeneous in 
terms of design and patients’ characteristics. For example, 
they included phase two studies with a shorter follow-up 
(12–14 weeks) in the NMA for a follow-up of 12–24 weeks, 
and reclassified some study arms (apremilast 40 mg was ana-
lyzed as 30 mg; ustekinumab 63 mg was analyzed as 90 mg). 
Moreover, they did not assess the treatments in subgroups 
differentiated by previous exposure to anti-TNFs and did not 
include abatacept. The present study was performed to fill 
this information gap.
The aim of our study was to assess the comparative 
efficacy and safety profile of considered biologic therapy 
regimens in adults with moderate to severe active PsA and 
provide meaningful information on the optimal treatment 
regimen in this condition. The efficacy of non-anti-TNF-α 
agents in patients with PsA not treated with anti-TNF-α 
(naive), patients previously treated with anti-TNF-α agents 
(experienced), and in subgroups with inadequate response or 
intolerance to anti-TNF-α (failure) was assessed.
Materials and methods
Data sources and searches
A systematic review was conducted according to the meth-
ods and recommendations from the PRISMA Extension 
Statement for Reporting of Systematic Reviews incorporat-
ing NMA [20] recommendations for conducting and inter-
preting the NMA (developed by the International Society 
for Pharmacoeconomics and Outcomes Research [ISPOR] 
Task Force [21] and Cipriani et al. [22]). The systematic 
review was registered in the PROSPERO database (registra-
tion number: 42017072200).
We identified eligible studies by searching MEDLINE via 
PubMed, Embase, and Cochrane Library. The search was 
performed from the inception of each database until July 
10, 2017; studies published in English were considered. The 
search strategy was based on the medical subject heading 
(MeSH) terms or Emtree terms combined with Boolean logi-
cal operators (Table 1). The search strategy was presented 
with the quality of reporting of meta-analyses (QUOROM) 
diagram (Fig. 1). Ethical approval and informed consent 
were not required because our study did not collect infor-
mation on patients or influence patient care. There were no 
restrictions with regard to endpoints, which allows to search 
for all possible adverse events, including severe, rare, and 
those which cannot be predicted prior to analysis. Similarly, 
refinements to the efficacy and effectiveness of the practice 
can be retrieved.
Selection criteria
Studies were identified using the search strategy by two 
reviewers. Study selection was based on the title and abstract 
and, if necessary, full-text articles. Studies were selected for 
inclusion in this analysis based on the following criteria: (1) 
participants were defined as adults (18 years or older) with 
a clinical diagnosis of moderate to severe PsA; (2) interven-
tion assessed was: abatacept, apremilast, secukinumab, and 
ustekinumab, and at least one study arm included a licensed 
dosage of those drug (EMA: [10, 13, 14, 16]); (3) com-
parator: another biologic agent or placebo; (4) outcomes: 
ACR20, ACR50, PASI75 (efficacy outcomes) and any AEs, 
SAEs, and withdrawals due to AEs (safety outcomes); (5) 
study: prospective, randomized trials with a follow-up of 
minimum 16 weeks but no longer than 28 weeks [maximum 
period for the assessment of response induction (EMA: [10, 
13, 14, 16])]. We selected only those novel biologics which 
have been registered by the EMA in the European Union or 
by the FDA in the United States for the treatment of PsA and 
Table 1  Keywords used in the searches of medical databases to identify relevant studies for abatacept, apremilast, secukinumab, and usteki-
numab for the treatment of patients with psoriatic arthritis
ABA abatacept, APR apremilast, CTLA-4 cytotoxic T-lymphocyte antigen 4, UST ustekinumab, SEC secukinumab
Area of meaning Keywords
Health problem (population) Psoriatic arthritis OR psoriasis arthritis OR psoriasis arthritic OR psoriatic arthropathy OR psoriatic arthropathies 
OR psoriatic polyarthritis OR Alibert Bazin disease
Intervention I (ABA) Abatacept OR belatacept OR BMS224818 OR BMS-224818 OR BMS 224818 OR LEA29Y OR nulojix OR 
orencia OR BMS 188667 OR BMS-188667 OR BMS188667 OR CTLA-4-Ig OR CTLA4-Ig OR CTLA4-Fc
Intervention II (APR) Apremilast OR otezla OR CC 10004 OR CC10004 OR CC-10004 OR small molecule
Intervention III (SEC) Secukinumab OR cosentyx OR AIN 457 OR AIN457 OR AIN-457
Intervention IV (UST) Ustekinumab OR stelara OR CNTO 1275 OR CNTO-1275 OR CNTO1275
Type of research PubMed: humans, clinical trial, randomized controlled trial, comparative study, controlled clinical trial; embase: 
humans, only embase, controlled clinical trials, randomized controlled trial; cochrane: cochrane central register 
of controlled trials
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which are not included in the anti-TNF-α group. The efficacy 
(ACR20, ACR50, PASI75) and safety (any AEs, SAEs, with-
drawal due to AEs) endpoints for the overall study popula-
tion and each subpopulation (anti-TNF-α-naive, anti-TNF-
α-failure, and anti-TNF-α-experienced) were included. The 
results among anti-TNF-α-experienced patients were used 
whenever information on anti-TNF-α-failure patients was 
not reported.
Full-text articles were included if they contained the 
required information about the study population, treatment 
regimen, and necessary data.
We excluded the following studies: (a) trials of novel 
(not registered in the European Union or USA) agents; (b) 
nonrandomized or uncontrolled studies; and (c) non-English 
publications. Unpublished studies, poster presentations, and 
conference abstracts were excluded if they did not provide 
information about the study design and results. Two study 
investigators independently reviewed the title and abstract 
of the studies identified in the search to exclude those that 
did not address the research question of interest based on 
prespecified inclusion and exclusion criteria.
The full text of the remaining articles was examined to 
determine whether it contained relevant information. Con-
flicts in study selection at this stage were resolved by con-
sensus, referring to the original article. However, there was 
a high degree of compatibility between the reviewers (95%). 
We searched the bibliographies of these selected articles, 
systematic reviews, and clinical trial registries (http://www.
clinicaltrials.gov) to identify any additional studies (hand 
searching).
Data extraction and quality assessment
Data were also extracted independently by two reviewers 
using predefined data extraction forms. Studies that met 
the inclusion criteria were independently reviewed by two 
reviewers who extracted the following information: study 
design (methodology), participants’ characteristics, inclu-
sion criteria, treatment regimen and concomitant therapy, 
duration of treatment, follow-up, sample size, arms size, 
and number of participants achieving predefined outcomes. 
The extracted data were then inspected by each author 
independently.
The intention-to-treat principle (ie, all patients lost to 
follow-up were considered treatment failures) was applied 
in the case of missing outcome data.
The methodological quality of eligible RCTs and the risk 
of bias within individual studies were assessed using the 
tool recommended by the Cochrane Collaboration, namely, 
domain-based evaluation. This tool allows to evaluate spe-
cific domains: sequence generation, allocation concealment, 
blinding of participants, blinding of outcome assessment, 
incomplete outcome data, selective outcome reporting, and 
“other issues”. We used the domain-based evaluation (“+”, 
low risk of bias; “−”, high risk of bias; “?”, unclear risk of 
bias) [23].
Data analysis and synthesis
The NMA was conducted with R software netmeta package 
[24]. The package incorporates the graph-theoretical method 
of NMA (vertices—treatments, edges—randomized com-
parisons) and provides a point estimate from the network 
along with 95% confidence intervals (CIs). This frequentist 
method is an alternative to standard NMA conducted within 
the Bayesian framework [25].
In the NMA, we used consistency and random effects mod-
els with adjustment for multi-arm studies. All eligible treat-
ment regimens with different doses and dosing intervals from 
the identified studies were included in the network and each 
treatment constituted one node (vertex in a graph). However, 
in the manuscript, only licensed dosage regimens were pre-
sented, that is, apremilast 30 mg, abatacept 10 mg, usteki-
numab 45 mg, and secukinumab 150 mg (anti-TNF-α naive) or 
Abbreviaons: see Table 1
Total number of hits in main databases:
PubMed [UST - 18; SEC - 4; APR - 9; ABA - 4]; 41
Embase [UST - 0; SEC - 0; APR - 0; ABA - 0]; 2 
Cochrane [UST - 74; SEC - 73; APR - 81; ABA - 12]; 266 
Duplicates removed: 19
Excluded because title and 
abstract revealed not 
appropriate: 262
Potentially relevant papers and 
screened for retrieval: 290
Excluded after reviewing 
full-text because:
- secondary analysis (not 
the outcome of interest) or 
open-label extension of the
included studies: 18
Studies retrieved for evaluation 
based on full-text paper: 28
Results of hand searching 
of reference lists: 2
Studies included in the systematic review: 11 RCTs:
UST – 3; SEC – 3; APR – 4; ABA – 1
Studies included in the mixed treatment comparison: 8 RCTs:
UST – 2; SEC – 2; APR – 3; ABA – 1
Fig. 1  Search flow diagram
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secukinumab 300 mg (anti-TNF-α failure, with plaque psoria-
sis). All comparisons, including suboptimal and experimental 
dosage regimens, were presented in supplementary file.
The heterogeneity of evidence was assessed using the Q 
test, I2 statistic, and tau values, and consistency was assessed 
using the splitting approach and comparison with direct evi-
dences. Publication bias was assessed by examining the fun-
nel plot for “small-study effects”.
The ranking of the treatment was conducted using the P 
score, a frequentist equivalent of surface under the cumula-
tive ranking or SUCRA. A higher P score corresponds to 
higher ranking for efficacy outcomes (ie, higher probability 
of ACR20, ACR50, etc) and higher ranking for safety [i.e., 
lower risk of adverse events (AEs)] [26]. The rankings for 
ACR20 and SAEs were combined in a Hasse diagram. Treat-
ments in the upper section of the diagram are more effica-
cious (ACR20) and safer (SAEs) than the other treatments 
connected to them by arrows. Treatments not connected by 
arrows represent “mutually incomparable” ones, that is, 
treatments whose comparative order was different for SAEs 
and ACR20 (e.g., treatment A ranked higher for ACR20 but 
ranked lower for SAEs than treatment B) [27].
Caution should be noted when interpreting the treatment 
ranking alone since it informs only about probability of a 
treatment to be the best while not incorporating the effect 
size of the difference between treatments directly. The aver-
age probability of an event (or sample sizes of hypothetical 
studies) along with relative measures from NMA should be 
considered with the treatment rankings [20, 28, 29].
The NMA was conducted for odds ratio (OR). The OR 
was used to calculate the average probability of an event for 
each treatment, using the assumed probability in the control 
arm. The latter was obtained from the meta-analysis of pla-
cebo arms from all studies included in the NMA, using the 
random effects model based on the Freeman-Tukey (double 
arcsine) transformed proportion. The average probability of 
ACR20 response to each treatment was used to calculate 
sample sizes for hypothetical between-treatment compara-
tive studies, using the likelihood-ratio test assuming 80% 
power and a two-sided alpha of 0.05.
A P value of less than 0.05 was considered statistically 
significant.
Results
Systematic review
The results of the systematic review are summarized in 
Fig.  1. In the systematic review, we revealed 11 RCTs 
presented in 11 publications [17, 30–39]. After careful 
consideration, we have chosen eight placebo-controlled 
studies referring to abatacept [30], apremilast, [31–33], 
secukinumab, [34, 35] and ustekinumab, [36, 37] homoge-
neous enough to be used in the NMA as well as providing 
results for the desired study endpoints in a 16- or 24-week 
follow-up period. Selected trials were excluded if they had 
an inadequate follow-up period limited to 12 weeks and/or 
a small study population [17, 38, 39].
The baseline characteristics of the studies as well as 
homogeneity assessment were summarized in Table S1. The 
baseline characteristics were generally similar between the 
studies, with a few exceptions. Some more heterogeneity was 
observed with regards to concomitant therapy, with metho-
trexate being allowed in most reference clinical trials. The 
majority of the included patients were treated with NSAIDs 
or DMARDs.
The methodological quality of RCTs in this review was 
categorized as high, and the risk of bias was assessed as 
low. The probability of occurrence of bias in most studies 
and domains was considered low (Fig. 2). All the included 
studies were randomized and almost all were double-blind 
[30, 31, 33–37]. Three of the studies specified the method 
of randomization [35–37] and the other three included a 
description of the blinding method [31, 35, 36].
The analysis of the homogeneity of the included tri-
als showed that the efficacy analysis, measured by ACR 
response, could be performed for ACR20 for three trials 
[31–33]. The analysis could also be performed for ACR50 
for two trials [32, 33] at week 16 and for five trials [30, 31, 
34, 35, 37] at week 24. The efficacy of psoriasis treatment 
based on PASI75 was assessed in two trials at week 16 [32, 
33] and four trials [31, 34, 35, 37] at week 24.
The safety analysis was performed for any AEs, SAEs, 
and withdrawals due to AEs in six trials [30–33, 36, 37] for 
a follow-up period of 24 weeks, and in two trials [34, 35] for 
a follow-up period of 16 weeks.
In all eight reference studies, biologic drugs proved sig-
nificantly more effective compared with placebo in terms of 
the ACR20 and ACR50 response rate [30–37].
NMA results
Eight trials were homogeneous enough to perform an NMA 
for the overall population as well as for the anti-TNF-α-
naive subpopulation [30–37]. Five studies were appropri-
ate to perform an NMA for the anti-TNF-α-experienced 
subpopulation, [30–33, 37] and four were appropriate for 
inadequate response to anti-TNF therapy and/or discontin-
ued treatment due to safety or tolerability issues (anti-TNF-α 
failure) [31, 33–35]. The results of abatacept treatment and 
ustekinumab treatment among anti-TNF-α-failure patients 
were not reported [30, 37]. Hence, data regarding anti-TNF-
α-experienced patients were used in the base-case analy-
ses for those drugs. Similarly, the results of secukinumab 
treatment among anti-TNF-α-experienced patients were not 
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reported and the results among anti-TNF-α-failure patients 
were used [34, 35].
The follow-up period of the reference studies varied from 
12 to 54 weeks, but the period of therapy administration 
incorporated into the dataset was a minimum of 16 weeks 
and did not exceed 24 weeks, as placebo control groups were 
available for this follow-up period. After 24 weeks of ther-
apy, patients in the placebo groups were re-randomized and 
active therapy study without placebo control was continued/
conducted.
Ranking of the treatments
The P score-based ranking of the treatments was presented 
in Table 2 (licensed dosages only) and in Table S2 in sup-
plementary file (all dosage regimens from clinical trials).
Considering ACR endpoints in the overall population 
and in the anti-TNF-α-naive subpopulation, secukinumab 
and abatacept were ranked higher than the other treat-
ments, while among anti–TNF-α-failure and anti-TNF-α-
experienced subpopulations, apremilast and secukinumab 
were the best options followed by ustekinumab. Usteki-
numab and secukinumab 150 mg were assessed as the saf-
est according to the P score for SAEs and withdrawals due 
to AEs.
The combined ranking of ACR20 and SAEs among 
patients from the overall population and anti-TNF-α-naive 
subpopulation revealed that secukinumab and ustekinumab 
were the best treatments. Ustekinumab was not as effica-
cious as secukinumab, but was a safer option. Among anti-
TNF-α-failure and anti-TNF-α-experienced subpopulations, 
apremilast and ustekinumab were the best treatment options. 
The use of secukinumab 300 mg was warranted within all 
populations along with the above options, but its low rank 
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Fig. 2  Risk of bias summary
Table 2  P score (overall rank based on P score among presented treatments)
Only the dosages recommended by the EMA were presented
ACR American College of Rheumatology, AE adverse event, PASI Psoriasis Area and Severity Index, SAE severe adverse event
a With supplementation of results from anti-TNF-α-experienced population for abatacept and ustekinumab
b With supplementation of results from anti–TNF-α-failure population for secukinumab
Abatacept Apremilast Secukinumab 150 Secukinumab 300 Ustekinumab
ACR20, overall population 0.639 (3) 0.407 (5) 0.815 (2) 0.932 (1) 0.510 (4)
ACR50, overall population 0.829 (1) 0.291 (5) 0.706 (3) 0.759 (2) 0.324 (4)
PASI75, overall population affected by psoriasis 0.323 (5) 0.386 (4) 0.604 (3) 0.794 (1) 0.789 (2)
Any AE, overall population 0.370 (4) 0.123 (5) 0.473 (2) 0.567 (1) 0.410 (3)
SAEs, overall population 0.320 (4) 0.489 (3) 0.561 (2) 0.273 (5) 0.594 (1)
Withdrawal due to AEs, overall population 0.462 (3) 0.076 (5) 0.629 (2) 0.420 (4) 0.794 (1)
ACR20, anti-TNF-α-naive patient population 0.712 (3) 0.354 (5) 0.867 (2) 0.899 (1) 0.380 (4)
ACR20, anti-TNF-α-failure  populationa 0.405 (5) 0.608 (2) 0.508 (4) 0.848 (1) 0.583 (3)
ACR20, anti-TNF-α-experienced  populationb 0.421 (5) 0.630 (2) 0.536 (4) 0.888 (1) 0.616 (3)
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for SAEs did not allow a direct comparison with other treat-
ments (Fig. 3).
Relative treatment effects
No significant differences between treatments were revealed 
with the exception of the following: (1) secukinumab 
300 mg increased the ACR20 response rate in the overall 
population in comparison with apremilast (P = 0.020); (2) 
apremilast reduced the rate of withdrawal due to AEs in 
comparison with ustekinumab (P = 0.002); (3) secukinumab 
150 and 300 mg increased the ACR20 response rate in the 
anti-TNF-α-naive subpopulation in comparison with apremi-
last and ustekinumab (P ranging from 0.004 to 0.024). There 
was no evidence for the higher efficacy of secukinumab over 
apremilast and/or ustekinumab in the anti-TNF-α-failure and 
anti-TNF-α-failure subpopulations (Table 3).
Compared with placebo, all treatments induced a higher 
rate of ACR20 and ACR50 responses in the overall popula-
tion. All treatments except abatacept significantly increased 
the rate of PASI75 response compared with placebo. 
Only apremilast reduced the rate of any AEs and SAEs in 
comparison with placebo. Ustekinumab was the only treat-
ment which significantly increased the rate of withdrawal 
due to AEs compared with control.
Abatacept and apremilast were no better than placebo 
in inducing ACR20 response among patients from the anti-
TNF-α-failure and anti-TNF-α-experienced subpopulations.
Sample sizes of hypothetical studies
Apart from comparing secukinumab with apremilast and 
ustekinumab in the anti-TNF-α-naive subpopulation, the 
NMA models for ACR20 revealed no significant additional 
clinical benefit of any active treatment over the other. How-
ever, the magnitude of differences in point estimates of the 
average response rates (Fig. 4) may suggest clinical advan-
tage of some treatments over the others, provided that the 
differences were not random or biased due to, for example, 
difference in trials’ design or participants’ characteristics.
The sample sizes of theoretical studies powered to prove 
the observed difference in ACR20 response between treat-
ments are presented in Table S6 in supplementary file (all 
dosage regimens from clinical trials) and in Table 4 (licensed 
dosage regimens).
Only studies comparing secukinumab with apremilast 
or ustekinumab should include a relatively small number 
of participants from the anti-TNF-α-naive subpopulation 
(below 150 patients). Other comparisons would require 
much higher sample sizes from the anti-TNF-α-naive sub-
population, ranging from 242 to 25,000 patients, which 
makes them much less probable to conduct. Among anti-
TNF-α-failure patients, the sample sizes for the comparison 
of secukinumab 300 mg with abatacept and ustekinumab 
were reasonable (120 and 304 patients, respectively).
Assessment of the networks
The level of heterogeneity of the effect sizes was high in 
the networks assessing response rates in the overall patient 
populations and anti-TNF-α-naive subpopulation (I2 ranging 
from 35.6 to 59.4%), while in the other networks level of 
heterogeneity did not exceed 21.2%.
The evidence for secukinumab (mainly different response 
rates for secukinumab 75 mg) was a major contribution to 
observed heterogeneity of the networks. Because secuki-
numab studies differed in design (four-arm vs. three-arm 
studies), different efficacy resulted in significant between-
design heterogeneity within the networks for ACR20 (over-
all population, P = 0.026; anti-TNF-α-naive population, 
P = 0.034) and PASI75 (P = 0.002).
The splitting approach revealed nonsignificant disa-
greement between direct and indirect evidences within all 
networks except for the comparison of PASI75 response 
between secukinumab 300 mg and placebo (P = 0.045) 
Fig. 3  Hasse diagram combining P scores for ACR20 and SAEs 
among patients from the overall study population and anti-TNF-α-
naive subpopulation (a), and anti-TNF-α-failure and anti-TNF-α-
experienced subpopulation (b)
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and between secukinumab 75 and 150 mg (P = 0.028). 
Overall, evidences for secukinumab were attributed with 
the greatest disagreement.
The results of all NMA models were convergent with 
ORs calculated for each study separately and the results 
of meta-analyses of direct evidences. There was no evi-
dence of publication bias in any of the networks.
Discussion
Although RCTs provide the best evidence for the relative 
efficacy of drugs, we did not identify such trials for non-
anti-TNF-α agents in PsA therapy. We also revealed no 
prospective observational studies available, so our study 
provided the first insights on the comparative efficacy of 
those drugs in relation with previous exposure to anti-
TNF-α agents. In the absence of head-to-head trials, the 
Table 3  Results of network meta-analyses: odds ratio with 95% confidence intervals in the brackets; in case of confidence intervals including 1 
the difference is statistically non-significant
(A) ACR20, overall population (above treatments labels; I2 = 56.7%) and ACR50, overall population (below labels; I2 = 38.3%); (B) PASI75, 
overall population (above labels; I2 = 59.4%) and any adverse events (below labels; I2 = 0%); (C) severe adverse events (above labels; I2 = 21.2%) 
and withdrawal due to adverse events (below labels; I2 = 0%); (D) ACR20, anti-TNF-α-naive subpopulation (above labels; I2 = 35.6%) and 
ACR20, anti-TNF-α-failure subpopulation (below labels; I2 = 0%); (E) ACR20, anti-TNF-α-failure subpopulation (above labels; I2 = 0%)
PLC, placebo; others, see Tables 1 and 2; OR > 1 below treatment labels means that the top treatment increases the odds for an outcome in com-
parison to the right one; OR > 1 above treatment labels means that the left treatment increases the odds for an outcome in comparison to the bot-
tom one. The treatment is better when increases odds for efficacy outcomes or decreases the odds for safety outcomes in comparison to the other
Bolded values indicate a statistically significant Odds Ratios for comparisons with placebo
Italicized values indicate a statistically significant Odds Ratios in comparisons with active comparators (other considered biologic)
A ABA_10 1.49 (0.44, 5.09) 3.85 (1.22, 12.08) 0.74 (0.21, 2.64) 0.53 (0.13, 2.08) 1.25 (0.30, 5.20)
0.20 (0.02, 1.90) APR_30 2.58 (1.66, 4.01) 0.49 (0.24, 1.01) 0.35 (0.15, 0.85) 0.84 (0.32, 2.18)
0.07 (0.01, 0.65) 0.36 (0.21, 0.63) PLC 0.19 (0.11, 0.34) 0.14 (0.06, 0.29) 0.33 (0.14, 0.76)
0.50 (0.05, 4.84) 2.49 (1.07, 5.78) 6.86 (3.64, 12.93) SEC_150 0.71 (0.35, 1.47) 1.70 (0.62, 4.70)
0.59 (0.06, 6.01) 2.91 (1.08, 7.85) 8.01 (3.52, 18.25) 1.17 (0.57, 2.41) SEC_300 2.39 (0.77, 7.44)
0.21 (0.02, 2.43) 1.07 (0.32, 3.55) 2.93 (1.01, 8.53) 0.43 (0.12, 1.48) 0.37 (0.10, 1.41) UST_45
B ABA_10 0.67 (0.04, 10.39) 3.33 (0.25, 44.04) 0.34 (0.02, 5.44) 0.18 (0.01, 3.30) 0.17 (0.01, 3.35)
1.24 (0.44, 3.49) APR_30 4.98 (1.97, 12.55) 0.51 (0.13, 1.97) 0.27 (0.06, 1.35) 0.25 (0.04, 1.49)
0.73 (0.27, 1.97) 0.58 (0.45, 0.75) PLC 0.10 (0.04, 0.27) 0.05 (0.01, 0.20) 0.05 (0.01, 0.23)
0.86 (0.30, 2.45) 0.69 (0.46, 1.04) 1.18 (0.85, 1.64) SEC_150 0.53 (0.15, 1.83) 0.48 (0.08, 2.96)
0.79 (0.26, 2.42) 0.64 (0.37, 1.11) 1.09 (0.67, 1.79) 0.93 (0.57, 1.52) SEC_300 0.91 (0.12, 6.81)
0.91 (0.32, 2.60) 0.73 (0.49, 1.10) 1.25 (0.91, 1.73) 1.06 (0.67, 1.68) 1.15 (0.63, 2.07) UST_45
C ABA_10 1.84 (0.18, 18.90) 1.80 (0.20, 16.09) 2.10 (0.18, 23.99) 1.04 (0.07, 14.65) 2.33 (0.19, 28.77)
2.56 (0.37, 17.60) APR_30 0.98 (0.45, 2.14) 1.14 (0.31, 4.26) 0.57 (0.11, 3.01) 1.26 (0.29, 5.44)
1.46 (0.23, 9.24) 0.57 (0.33, 1.00) PLC 1.17 (0.41, 3.37) 0.58 (0.13, 2.54) 1.30 (0.38, 4.44)
0.66 (0.07, 6.28) 0.26 (0.06, 1.05) 0.45 (0.13, 1.64) SEC_150 0.50 (0.11, 2.34) 1.11 (0.22, 5.61)
1.15 (0.10, 12.69) 0.45 (0.09, 2.32) 0.78 (0.17, 3.67) 1.73 (0.27, 10.92) SEC_300 2.23 (0.33, 15.26)
0.40 (0.05, 3.31) 0.16 (0.05, 0.50) 0.28 (0.10, 0.76) 0.61 (0.12, 3.12) 0.35 (0.06, 2.23) UST_45
D ABA_10 2.07 (0.55, 7.76) 5.00 (1.43, 17.53) 0.74 (0.19, 2.92) 0.65 (0.15, 2.85) 1.93 (0.49, 7.51)
1.76 (0.14, 22.89) APR_30 2.41 (1.60, 3.64) 0.36 (0.18, 0.72) 0.31 (0.13, 0.76) 0.93 (0.48, 1.81)
0.45 (0.07, 3.07) 0.26 (0.05, 1.40) PLC 0.15 (0.08, 0.26) 0.13 (0.06, 0.28) 0.39 (0.23, 0.65)
1.32 (0.17, 10.15) 0.75 (0.12, 4.68) 2.92 (1.46, 5.85) SEC_150 0.88 (0.42, 1.85) 2.61 (1.21, 5.65)
2.96 (0.34, 25.34) 1.68 (0.24, 11.83) 6.57 (2.51, 17.19) 2.25 (0.92, 5.46) SEC_300 2.97 (1.15, 7.62)
1.53 (0.19, 12.70) 0.87 (0.13, 5.91) 3.41 (1.41, 8.22) 1.17 (0.38, 3.58) 0.52 (0.14, 1.91) UST_45
E ABA_10 0.64 (0.08, 5.37) 2.22 (0.33, 15.18) 0.76 (0.10, 5.86) 0.34 (0.04, 2.90) 0.65 (0.08, 5.40)
APR_30 3.47 (1.40, 8.59) 1.19 (0.38, 3.72) 0.53 (0.14, 1.98) 1.02 (0.29, 3.60)
PLC 0.34 (0.17, 0.68) 0.15 (0.06, 0.40) 0.29 (0.12, 0.71)
SEC_150 0.45 (0.18, 1.08) 0.86 (0.28, 2.63)
SEC_300 1.93 (0.52, 7.10)
UST_45
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results may be useful to facilitate relevant decision making 
in terms of medical management and may inform a proper 
and effective selection of biologics in the management of 
active PsA in clinical guidelines and everyday practice.
Combining direct and indirect evidence from eight 
reference clinical trials, including anti-TNF-α-naive, 
anti-TNF-α-failure, or anti-TNF-α-experienced patients, 
allowed us to make several key observations.
Significant differences in the ACR20 response rate were 
revealed between secukinumab 150 mg and apremilast 
20 mg and between secukinumab 300 mg and apremilast 
20 or 30 mg. Any AEs occurred more often in apremilast 
20 and 30 mg compared with placebo, but also compared 
with secukinumab 150 mg. No significant differences were 
revealed for SAEs among biologics and in the comparison 
of biologics with placebo.
Fig. 4  The average probability of a ACR20, overall population; b 
ACR50, overall population; c PASI75, overall population; d any 
adverse events; e severe adverse events; f withdrawals due to adverse 
events; g ACR20, anti-TNF-α-failure subpopulation; h ACR20, anti-
TNF-α-experienced subpopulation; i ACR20, anti-TNF-α-naive sub-
population. Dashed line indicates assumed control rate (meta-analysis 
of placebo arms)
Table 4  Total sample sizes of comparative efficacy studies with par-
ticipants from anti-TNF-α-naive subpopulation (above treatment 
labels) and anti-TNF-α-failure subpopulation (below treatment labels)
The recommended dosage of the treatments is included
NA, not applicable (only secukinumab 300  mg is recommended in 
anti–TNF-α-failure population)
Abatacept 242 1432 724 296
460 Apremilast 122 98 24,938
NA NA Secuki-
numab 
150
8564 142
120 480 NA Secuki-
numab 
300
112
822 7176 NA 304 Ustekinumab
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In the overall population of PsA patients, it was con-
firmed that all approved agents, excluding abatacept 3 mg, 
are effective over placebo. Secukinumab 300 mg, secuki-
numab 150 mg, and abatacept were ranked the highest for 
the ACR20 response rate assessment in 16–24 weeks of 
follow-up. In the analyzed subpopulations, secukinumab 
300 mg was ranked the highest for the ACR20 response 
rate, while in the anti-TNF-α-experienced subpopulation, 
secukinumab 300 mg and apremilast 30 mg had the high-
est rank.
The safest in terms of any AEs were secukinumab 75 mg 
and abatacept 30/10  mg. P score comparison for both 
ACR20 and SAEs revealed the highest rank for secukinumab 
300 mg, ustekinumab, and secukinumab 150 mg. Apremilast 
was also ranked high for the anti-TNF-α-failure and anti-
TNF-α-experienced subpopulations.
Our results would be especially valid in the case of 
patients who had persistently active disease despite tradi-
tional NSAID and/or DMARD therapy, or who do not tol-
erate NSAIDs and/or DMARDs, or those who were nonre-
sponsive to anti-TNF-α therapy. Based on current data, the 
probability of failure to achieve ACR20 response in anti-
TNF-α trials range from 25 to 50% [40–42]. In the case 
of such patients, the results of this innovative analysis are 
especially valid and clinically meaningful.
In a review of medical databases, we identified papers 
referring to the assessment of non-anti-TNF-α agents in PsA, 
but no study among PsA patients differentiated by previous 
anti-TNF-α treatment has been performed to date.
In a study by Ungprasert et al. [43], a total of 12 RCTs 
were identified and included in data analyses. Patients 
who received older anti-TNF-α (etanercept, infliximab, 
adalimumab, and golimumab) had a significantly higher 
chance of achieving ACR20 response compared with those 
receiving apremilast, ustekinumab, and certolizumab. 
The authors also revealed that the likelihood of achieving 
ACR20 response among secukinumab users (at a dose of 
150 and 300 mg weekly) was significantly higher compared 
with apremilast or ustekinumab users, and the likelihood of 
achieving ACR20 response was higher among secukinumab 
users (at a dose of 150 and 300 mg weekly) compared with 
apremilast, ustekinumab, and certolizumab, even though 
the difference did not reach significance in a few compari-
sons (secukinumab 300 mg vs certolizumab, secukinumab 
150 mg vs ustekinumab 90 mg, and secukinumab 300 mg 
vs ustekinumab 90 mg) [43]. The results of higher efficacy 
in terms of the ACR20 assessment were consistent with 
our findings suggesting the higher clinical effectiveness of 
secukinumab compared with other non-anti-TNF-α biolog-
ics; no safety profile comparisons between included drugs 
were performed.
In another study [44], a meta-analysis of abatacept, apre-
milast, secukinumab, and ustekinumab was performed. 
Two relevant studies were found to evaluate ustekinumab. 
The pooled results showed that the RRs for ACR20 versus 
placebo were 2.17 (95% CI 1.71–2.76) and 1.95 (95% CI 
1.52–2.50) for ustekinumab 90 mg and ustekinumab 45 mg, 
respectively. A meta-analysis across the trials resulted in 
RRs for ACR20 versus placebo of 3.31 (2.04–5.36) for 
secukinumab 300 mg, 5.82 (1.56–21.71) for secukinumab 
150 mg, and 4.47 (0.66–30.26) for secukinumab 75 mg. 
A meta-analysis resulted in RRs for apremilast 30 mg and 
apremilast 20 mg versus placebo of 1.98 (1.64–2.38) and 
1.70 (1.40–2.06), respectively [44]. No relative assessments 
among the considered drugs were performed. Biologics have 
also demonstrated relatively good safety on a short as well as 
medium follow-up and no major safety issues were observed 
[44].
In another study [19], all four non-anti-TNF-α biologics 
were compared relatively among anti-TNF-α-experienced 
patients. There were no significantly different odds of 
achieving ACR20 response between those four agents in 
any studied dosages. These conclusions were generally in 
line with our findings.
The NMA models indicated a potential additional clinical 
benefit of secukinumab, abatacept, and apremilast dosages 
recommended by the EMA over the lower one used in the 
studies. Moreover, they indicated no or a small additional 
benefit of using ustekinumab 90 mg instead of ustekinumab 
45 mg, which is also in line with the recommended dosage 
regimen.
It seems that the less strict approach to assess the homo-
geneity of studies included in the NMA used by Song and 
Lee [18] resulted in efficacy and dose–response relation-
ship of apremilast, secukinumab, and ustekinumab. The 
conclusion for apremilast and secukinumab is in line with 
our findings. However, this study (Table S2 in supplemen-
tary file) as well as EMA recommendations did not indicate 
superior efficacy or safety profile of ustekinumab 90 mg over 
45 mg. Additionally, they found no significant difference 
in the induction of ACR20 response between secukinumab 
300 mg and apremilast 30 mg (OR 2.49; 95% Bayesian cred-
ible interval [CrI], 0.87, 6.64), but significant difference 
between secukinumab 300 mg and apremilast 20 mg (OR, 
3.24; 95% CrI, 1.10, 8.37) was found. This study provided 
similar point estimates of the OR for the above compari-
sons (OR, 2.84; 95% CI, 1.18, 6.86 and OR, 3.57; 95% CI, 
1.48, 8.64, respectively), but revealed significance for both. 
Song and Lee included a study by Schett et al. [39] in their 
models, and reclassified the apremilast arm of that study, 
assuming that a dose of 40 mg will have equal efficacy as 
that of 30 mg. The inclusion of that evidence despite lower 
credibility (phase II trial, no licensed dosage) resulted in an 
increase of the number of evidences in the network (pre-
cision of the estimates) and the average response rate for 
apremilast 30 mg. Hence, no significance of the results of 
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the comparison with secukinumab was shown. The number 
of serious adverse events did not differ significantly among 
apremilast, secukinumab, ustekinumab and placebo; no 
significant differences were revealed in the safety between 
the interventions at different doses; conclusions occured 
the same as in our study. The ranking probability based on 
SUCRA indicated that ustekinumab 90 mg had the highest 
probability of being the most tolerable treatment followed 
by ustekinumab 45 mg [18].
Due to study limitations and differences between the 
compared studies, the interpretations should be considered 
with caution.
The limitations of the present study must be considered. 
First, the follow-up times ranged from 16 to 24 weeks, and 
were of medium duration. This period may be too short to 
evaluate the long-term effects. Thus, the results may not 
apply to long-term treatment but only to the response-induc-
tion phase of the treatment. The results may give meaningful 
information on the rate of patients with a clinical indication 
for long-term treatment.
Another issue is the comparability of the studies used 
for comparisons. The key issue for any indirect compari-
sons is the similarity of the patient populations. The studies 
included in the NMA were considered to be comparable in 
terms of the most important and essential parameters. The 
RCTs were homogenous in terms of the baseline charac-
teristics of patients (similar female-to-male ratio, average 
age, and baseline disease activity as reflected by a similar 
patient’s global assessment of disease activity scores) and 
follow-up periods with outcomes reported. The definitions 
of active disease were consistent across the studies (ie, ≥ 3 
swollen joints and ≥ 3 tender joints) and all studies allowed 
concomitant use of stable doses of DMARDs and steroids. 
On the other hand, the inevitable differences between the 
study characteristics could affect the results of indirect com-
parisons to some extent.
The available evidence for abatacept is limited. Only one 
phase II study with 40 participants per group met the inclu-
sion criteria. Due to the small sample size and low number 
of evidence, the precision of results for abatacept treatment 
was relatively low and there was less credibility in compari-
son with other treatments.
Findings from the NMA need to be interpreted with cau-
tion since these trials did not always mirror clinical practice. 
Direct studies are needed to determine the relative efficacy 
and safety of the considered drugs.
The comprehensiveness of data comparisons is the major 
strength of this study, as this indirect comparison technique 
allows us to compare various pairs of biological agents for 
which direct comparison data are not available. We also 
exclusively included only RCTs that are considered as the 
most valid study design to prove the efficacy of an inter-
vention. Thus, the primary data included in these analyses 
were of high quality. Another strength of this study was the 
methodological level with which it was conducted and the 
useful information it provided for clinicians and for health-
care decision makers.
In the protocol registered at PROSPERO also alefacept 
and brodalumab were presented but in the current stage of 
the project four biologics authorized both by FDA and EMA 
in PsA therapy were included. We have focused on ACR20 
as primary and the most important outcome evaluated but 
results for other outcomes (ACR70 and ACR50) should also 
be presented on further steps of the project.
Our study revealed no significant differences among 
non–anti-TNF-α biologics in the treatment of PsA in the 
comparisons performed with regards to the highest efficacy 
and safety. Both in the overall population and in the ana-
lyzed subpopulations, secukinumab 300 mg was ranked the 
highest for the ACR20 response rate. Secukinumab 300 mg 
was the safest drug in terms of any AEs, and ustekinumab 
90 mg presented the lowest overall risk of SAEs. Long-term 
studies based on a large number patient groups are needed 
to determine the relative efficacy and safety of abatacept, 
apremilast, secukinumab, and ustekinumab in PsA.
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